Watch Out GSK! China’s Homegrown Shingles Vaccine Set To Soar

Other Competitors Looming

Although the domestic developer did not provide sales figures for 2023, a new homegrown shingles vaccine in China is poised to eat into the market share of GSK’s Shingrix in the country.

herpes zoster vaccine
China's herpes zoster vaccine market set for more entrants • Source: Shutterstock

More from China

More from Focus On Asia